All News
Opioids are Like Guns in the Hands of Children
The opioid abuse epidemic is well known and the focus of many regulators and health care personnel. The problem also affects the youngest Americans, according to a recent Washington Post article.
Read Article
ACP Gout Guidelines Reviewed and Critiqued by Rheumatologists
ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.
Read Article
Decreased CD4 T Cells with Rituximab Infusions
Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen on B cells and when administered causes a marked depletion of CD20+ B cells.
Read Article
When Cheap Generics Morph Into Expensive Prescriptions
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
Read Article
The RheumNow Week in Review – 28 October 2016
Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
Read Article
POSTURE Study: Apremilast Fails in Ankylosing Spondylitis
ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.
Read Article
October-September 2016 Top Social Media News
Following is a list of top tweets in September and October 2016; they were selected based on the number of clicks, retweets and likes by the viewership. More than 40,000 people were reached with the first one on our list.
Read Article
ACP Guidelines on the Diagnosis and Treatment of Low Back Pain
Low back pain (LBP) is the fifth most common reason for all physician visits in the United States and nearly 25% of all U.S. adults have had LBP in the last 3 months and nearly 6% reported at least 1 episode of severe acute low back pain in the last 1-year.
Read Article
Nor-Switch Study Shows it's Safe to Switch to a Biosimilar
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Read Article
Review of Herpes Zoster with Immunosuppression and Autoimmune Disease
Researchers from the University of British Columbia reported on their systematic review and meta-analysis of risk of herpes zoster (HZ) in patients receiving biologics, DMARDs and/or corticosteroids for autoimmune diseases.
Read Article
RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Read Article
Cannibis Abusers Have Decreased Bone Mass, More Fractures
People who regularly smoke large amounts of cannabis have reduced bone density and are more prone to fractures, research has found. The study also found that heavy cannabis users have a lower body weight and a reduced body mass index (BMI), which could contribute to thinning of their bones.
Read Article
My Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).
Long-Term Outcomes of Aromatase Inhibitor Arthralgias
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
Read Article
Those with Osteoporotic Fractures are Going Untreated
The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.
Read Article
RheumNow Week in Review – 7 October 2016
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
Read Article
Biosimilar Reports – October 2016
RheumNow will periodically review this subject with “Biosimilar Reports” providing updates, news, new publications, overview articles and research results impacting to biosimilar development and use.
Read Article
Infection Rates Stable in JIA With Anti-TNF Therapy
Children with juvenile idiopathic arthritis (JIA) treated with biologic therapies were at no higher risk for hospitalized infections than those treated with methotrexate alone, But, higher rates were seen with anakinra in systemic JIA.
Read Article
Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis
Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.
Read Article
BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection
Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.
Read Article